We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Hepatic Resection Can Provide Long-Term Survival

By HospiMedica International staff writers
Posted on 18 Jul 2012
A new study suggests that hepatic resection can provide long–term survival benefit in selected patients with non-early-stage hepatocellular carcinoma (HCC).

Researchers at Kaohsiung Medical University (Taiwan) conducted a study involving 478 patients with HCC who underwent liver resection between 1991 and 2006. More...
Of these, 318 were Barcelona Clinical Liver Cancer Classification (BCLC) stage B, and 160 and BCLC stage C. The researchers examined and analyzed factors involved in overall survival and recurrence. The results showed that after a median follow–up of 29.5 months, 304 of the patients had died, putting the cumulative overall survival rate at five years at 46.5% in BCLC stage B patients, and 29.1% in stage C patients.

Multivariate analysis disclosed that serum albumin levels below or equal to 4 g/dL, indocyanine green retention rate at 15 minutes of over 10%, serum creatinine higher than 1.2 mg/dL, multinodularity, Edmondson stage III or IV in tumor cell differentiation, and the presence of macroscopic vascular invasion were independent risk factors of poor overall survival. There were 331 patients with tumor recurrence after resection, and the recurrence rate was less in BCLC stage B than that in BCLC stage C, and was associated with cut margins smaller than one centimeter. The study was published ahead of print on July 3, 2012, in Surgery.

“Hepatic resection can provide long-term survival benefit in selected BCLC stage B or C patients with compensated liver function, especially in those presenting with a single neoplasm without vascular invasion,” concluded lead author Wen-Tsan Chang, MD, and colleagues of the division of hepatobiliary and pancreatic surgery.

The biggest concern about liver resection is that following the operation, the patient can develop liver failure, which occurs if the remaining portion of the liver is inadequate to provide the necessary support for life. Even in carefully selected patients, about 10% of them are expected to die shortly after surgery, usually because of liver failure. In patients with HCC, liver resection is generally limited to patients with one or two small (5 cm or less) tumors and confined to the liver with no invasion of the blood vessels. As a result of these strict guidelines, in practice, very few patients with HCC can undergo liver resection.

Related Links:

Kaohsiung Medical University




Gold Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Mammo DR Retrofit Solution
DR Retrofit Mammography
Adjustable Mobile Barrier
M-458
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.